382 related articles for article (PubMed ID: 32779746)
1. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH; Artz AS; Undevia SD; Pai RK; Del Cerro P; Horowitz S; Godley LA; Hart J; Innocenti F; Larson RA; Odenike OM; Stock W; Van Besien K
Leuk Lymphoma; 2010 Dec; 51(12):2240-9. PubMed ID: 20919852
[TBL] [Abstract][Full Text] [Related]
3. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
4. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
5. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
[TBL] [Abstract][Full Text] [Related]
6. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Berger K; Schopohl D; Rieger C; Ostermann H
Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
8. Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.
Hoy SM; Lyseng-Williamson KA
Paediatr Drugs; 2007; 9(4):271-8. PubMed ID: 17705566
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
10. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Nagler A; Labopin M; Berger R; Bunjes D; Campos A; Socié G; Kröger N; Goker H; Yakoub-Agha I; Shimoni A; Mohty M; Rocha V
Bone Marrow Transplant; 2014 May; 49(5):628-33. PubMed ID: 24535127
[TBL] [Abstract][Full Text] [Related]
12. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
13. Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
Abate ME; Paioli A; Cammelli S; Cesari M; Longhi A; Palmerini E; Ferrari S; Carretta E; Picci P; Piscaglia F
Bone Marrow Transplant; 2018 May; 53(5):591-599. PubMed ID: 29335623
[TBL] [Abstract][Full Text] [Related]
14. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
[TBL] [Abstract][Full Text] [Related]
15. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193
[TBL] [Abstract][Full Text] [Related]
17. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
[TBL] [Abstract][Full Text] [Related]
18. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
19. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Andersson BS; Thall PF; Madden T; Couriel D; Wang X; Tran HT; Anderlini P; de Lima M; Gajewski J; Champlin RE
Biol Blood Marrow Transplant; 2002; 8(9):477-85. PubMed ID: 12374452
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
McCune JS; Batchelder A; Deeg HJ; Gooley T; Cole S; Phillips B; Schoch HG; McDonald GB
Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
